Fei Wang
Kanazawa University
4 Papers
48 Citations
Fei Wang is an academic researcher from Kanazawa University. The author has contributed to research in topics: Downregulation and upregulation & Proinflammatory cytokine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Sustained delivery of sphingosine-1-phosphate using poly(lactic-co-glycolic acid)-based microparticles stimulates Akt/ERK-eNOS mediated angiogenesis and vascular maturation restoring blood flow in ischemic limbs of mice.
Xun Qi,Yasuo Okamoto,Tomomi Murakawa,Fei Wang,Osamu Oyama,Ryunosuke Ohkawa,Kazuaki Yoshioka,Wa Du,Naotoshi Sugimoto,Yutaka Yatomi,Noriko Takuwa,Noriko Takuwa,Yoh Takuwa +12 more
TL;DR: Results indicate that PLGA-based, sustained local delivery of S1P is a potentially useful therapeutic modality for stimulating post-ischemic angiogenesis.
47
Patent
Therapeutic agent for atherosclerosis comprising s1p2 receptor antagonist
Takuwa Yoh,Yasuo Okamoto,Fei Wang +2 more
- 21 Jul 2011
TL;DR: In this paper, a therapeutic agent for atherosclerosis consisting of an S1P2 receptor antagonist as an active ingredient was described. But the drug was not tested in clinical trials.
3
Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice
Fei Wang,Yasuo Okamoto,Isao Inoki,Kazuaki Yoshioka,Wa Du,Xun Qi,Noriko Takuwa,Noriko Takuwa,Koichi Gonda,Yasuhiko Yamamoto,Ryunosuke Ohkawa,Takumi Nishiuchi,Naotoshi Sugimoto,Yutaka Yatomi,Kunitoshi Mitsumori,Masahide Asano,Makoto Kinoshita,Yoh Takuwa +17 more
TL;DR: It is concluded that S1PR2 plays a critical role in atherogenesis and may serve as a novel therapeutic target for atherosclerosis.
S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species
Noriko Takuwa,Sei Ichiro Ohkura,Shin Ichiro Takashima,Keisuke Ohtani,Yasuo Okamoto,Tamotsu Tanaka,Kaoru Hirano,Soichiro Usui,Fei Wang,Wa Du,Kazuaki Yoshioka,Yoshiko Banno,Motoko Sasaki,Ikuyo Ichi,Miwa Okamura,Naotoshi Sugimoto,Kiyomi Mizugishi,Yasuni Nakanuma,Isao Ishii,Masayuki Takamura,Shuichi Kaneko,Shosuke Kojo,Kiyoshi Satouchi,Kunitoshi Mitumori,Jerold Chun,Yoh Takuwa +25 more
TL;DR: It is suggested that chronic activation of SPHK1-S1P signalling results in both pathological cardiac remodelling through ROS mediated by S1P3 and favourable cardioprotective effects.